Blood Lipid Responses to Diet Macronutrients
BoLD
Investigating Blood Lipid Responses to Dietary Macronutrient Content
1 other identifier
interventional
60
1 country
2
Brief Summary
The macronutrient composition of a diet (proportions of carbohydrates, fats and proteins) strongly influences the way the body stores and utilises substrates (e.g., fats and sugars), which in turn influences the risk of developing cardiometabolic diseases (e.g., coronary artery disease or insulin resistance). The optimal dietary composition to lower the risk of cardiometabolic disease is unknown. In a randomized, parallel design, this study will investigate how the overconsumption of carbohydrates and fats affects blood lipid responses and liver metabolism in adults free from metabolic disease. By genotyping participants, the interaction between macronutrient content and an individual's genes on blood lipid responses and liver metabolism will be examined.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2023
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 9, 2023
CompletedStudy Start
First participant enrolled
February 15, 2023
CompletedFirst Posted
Study publicly available on registry
August 3, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2028
May 11, 2026
May 1, 2026
4.9 years
January 9, 2023
May 6, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change in plasma triglyceride concentrations [mmol/L]
Change in plasma triglyceride concentrations in response to consumption of macronutrient meal will be measured by basic clinical chemistry before and at the end of the dietary intervention.
Pre- and post-diet [21-28 days]
Secondary Outcomes (5)
Change in liver fat content [%]
Pre- and post-diet [21-28 days]
Change in cardiac fat content [%]
Pre- and post-diet [21-28 days]
Change in the contribution of dietary and adipose tissue derived fatty acids to very low density lipoprotein-triglyceride (VLDL-TG) palmitate
Pre- and post-diet [21-28 days]
Change in hepatic fatty acid synthesis
Pre- and post-diet [21-28 days]
Influence of genotype on the change in plasma lipid content [mmol/L]
Pre- and post-diet [21-28 days]
Study Arms (2)
High carbohydrate, low fat diet
EXPERIMENTAL65% of energy is derived from carbohydrates, 20% from fat, and 15% from protein.
High fat, low carbohydrate diet
EXPERIMENTAL65% of energy is derived from fat, 20% from carbohydrates, and 15% from protein.
Interventions
Eucaloric diet enriched in either carbohydrates or fat (both contributing to 65% total energy intake)
Eligibility Criteria
You may qualify if:
- Participant is willing and able to give informed consent for participation in the study.
- Male or Female, aged ≥18 to ≤65 years
- Body mass index (BMI) ≥19 to ≤35 kg/m2
- No medical condition or relevant drug therapy that is known to affect the liver, adipose tissue, or cardiac metabolism.
- Weight stable for the previous 3 months
You may not qualify if:
- Aged \<18 or \>65 years
- BMI \<19 or \>35 kg/m2
- A blood haemoglobin \<135 mg/dL for men and \<120 mg/dL for women
- Donated (or lost) ≥250 mL of blood in the previous two months
- On a weight loss diet or decreased their body weight by \>5% in the previous 3 months
- Currently adhering to or have consumed in the previous 3 months a diet with a notably altered macro-nutrient content (e.g. high-fat - low-carbohydrate diet)
- Have increased their body weight by \>5% in the previous 3 months
- Any metabolic condition or relevant drug therapy
- Current smoker
- History of alcoholism or a greater than recommended alcohol intake (\>30 g of alcohol daily for men and \>20 g of alcohol daily for women)
- History of albumin allergy.
- Pregnant or nursing mothers
- History of severe claustrophobia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford
Oxford, OX3 7LE, United Kingdom
Oxford Centre for Diabetes, Endocrinology and Metabolism
Oxford, OX3 7LE, United Kingdom
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Leane Hodson
University of Oxford
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 9, 2023
First Posted
August 3, 2023
Study Start
February 15, 2023
Primary Completion (Estimated)
January 1, 2028
Study Completion (Estimated)
January 1, 2028
Last Updated
May 11, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share
There are no plans to share IPD with other researchers